Stifel Has Red-Hot Biotech Stocks to Buy With Huge Upside Potential

By Lee Jackson Updated Jan 11, 5:33PM EST · Published Sep 21, 8:45AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Stifel Has Red-Hot Biotech Stocks to Buy With Huge Upside Potential — © nevodka / iStock

Needless to say, the biotech world has had a volatile 18 months. Some of the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, are still looking like top plays for investors. However, you can bet that the shrill rhetoric from politicians over drug pricing could pick up as we edge ever closer to the midterm elections.

A series of new Stifel research reports focus on three companies that have upcoming clinical data that could prove to be huge. Numerous reasons why the stocks are very attractive now are cited, and all three are rated Buy at Stifel.

Argenx

The stock was hit on some recent clinical safety data, and Stifel says buy the dip. Argenx S.E. (NASDAQ: ARGX) is a Netherlands-based biopharmaceutical company that creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The pipeline of antibody therapeutics is focused on cancer and autoimmune indications.

The safety issue hit the stock hard, and Stifel noted this:

We think investors are overreacting to the additional safety data disclosed from efgartigimod’s Phase 2 study in immune thrombocytopenia (ITP) and would be buyers on the weakness. Although, we recognize it may take additional data, which the company expects to present at the American Society of Hematology (ASH) in December, for some investors to get more comfortable, we know: (1) patients treated with efgartigimod in the study and who were in response (had a platelet count of 50×10^9/L) did not experience bleeds.

The Stifel price target is a massive $139, but the Wall Street consensus target is even higher at $150.26. The stock closed Thursday at $80.20 a share.

[nativounit]

Neurocrine Biosciences

This company is partnering with a big pharmaceutical company, and the data have been very solid. Neurocrine Biosciences Inc. (NASDAQ: NBIX) is a biopharma company focused on developing and commercializing therapies for neurological and endocrine disorders. The company’s lead asset is Ingrezza, approved for the treatment of tardive dyskinesia and in development for the treatment of Tourette syndrome.

The company also partnered with AbbVie on elagolix, in development for the treatment of endometriosis and uterine fibroids, and is developing opicapone as an adjunct therapy for Parkinson’s disease. Stifel noted this:

We recently hosted an investor meeting with CEO Kevin Gorman, CFO Matt Abernethy, CCO Eric Benevich, CMO Eiry Roberts and CBO Kyle Gano. The primary area of focus of our meeting was the opportunity for and probability-of-success for valbenazine in Tourette’s syndrome (TS), where ahead of data in December we’ve recently become more bullish based on our additional research. A key point of discussion during our meeting was the smart trial design the company has employed in TS: (1) conservative statistical powering, based on other successful studies in the space, (2) interim looks for dose optimization, mitigating the risk that tripped the company up in prior phase 2’s and (3) a longer treatment duration.

Stifel has a $142 price target. The consensus target is $134.46, and shares closed on Thursday at $120.23.

[recirclink id=493960]

Vertex Pharmaceuticals

This has long been considered a buyout candidate and it has traded sideways since the summer. Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) engages in discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis and hepatitis C.

Wall Street as a whole has long been very positive on the stock, and some have indicated that the company could have as much as $10 in potential earnings-per-share power. Stifel analysts are very positive and noted this:

We recently hosted a tour of Vertex’s new San Diego research facility with a group of investors, during which we delved into the details of the company’s R&D engine with Dr. Paul Negulescu, SVP and Site Head of San Diego Research and Eric Rojas, Senior Director of IR. We left our meeting with affirmed conviction in the company’s very strong barriers to entry in Cystic Fibrosis, and optimism (though not captured in our model) that the CF approach can be leveraged onto other diseases. The new facility, open as of a few months ago, focuses 33% of its efforts on CF (the same magnitude of applied resources as previously), 33% on pain, and the other third of its bandwidth on other disease areas. The company reaffirmed that the journey in CF is not over, with research focused on potentially curative and/or single, more potent corrector (ie. two drug) regimens.

The $200 Stifel price target compares with a $196.52 consensus target. The shares closed Thursday at $180.52.

[wallst_email_signup]

One smaller company has huge upside to the Stifel target, and the two older and more mature companies may represent safer bets for aggressive accounts looking to add biotech to portfolios.

About the Author Lee Jackson →

Lee Jackson has covered Wall Street analysts' equity and debt research and equity strategy daily for 24/7 Wall St. since 2012. His broad and diverse career, which included a stint as the creative services director at the NBC affiliate in Austin, Texas, gives him unique insight into the financial industry and world.

Lee Jackson's journey in the financial industry spans over 30 years, with nearly two decades as an institutional equity salesperson at Bear Stearns, Lehman Brothers, and Morgan Stanley. His career was marked by his presence on the sell side during pivotal Wall Street events, from the dot.com rise and bubble to the Long Term Capital Management debacle, 9/11, and the Great Recession of 2008. This is a testament to his resilience and adaptability in the face of market volatility.

Lee Jackson’s practical financial industry experience, acquired from a career at some of the biggest banks and brokerage firms, is complemented by a lifetime of writing on various platforms. This unique combination allows him to shed light on the intricacies and workings of Wall Street in a way that only someone with deep insider experience and knowledge can. Moreover, his extensive network across Wall Street continues to provide direct access for him and 24/7 Wall St., a privilege few firms enjoy.

Since 2012, Jackson’s work for 24/7 Wall St. has been featured in Barron’s, Yahoo Finance, MarketWatch, Business Insider, TradingView, Real Money, The Street, Seeking Alpha, Benzinga, and other media outlets. He attended the prestigious Cranbrook Schools in Bloomfield Hills, Michigan, and has a degree in broadcasting from the Specs Howard School of Media Arts.